• Revenues declined 29% year-over-year to $1.9 million
• Net loss increased 23% year-over-year to $94.1 million
• Net tangible assets per share declined from $1.74 to ($0.01)

Anteris Technologies Global Corp. (ASX: AVR, NASDAQ: AVR) reported its financial results for the year ended December 31, 2025. The company's revenues declined 29% year-over-year to $1.9 million, while its net loss increased 23% to $94.1 million. The company's net tangible assets per share declined from $1.74 as of December 31, 2024 to ($0.01) as of December 31, 2025. No dividends were proposed, declared, or issued during the year. The company's Admedus Biomanufacturing Pty Ltd and Admedus (Australia) Pty Ltd subsidiaries were deregistered during the year, with no material impact on the group. As of December 31, 2025, all funds raised from the company's initial public offering in December 2024 had been fully utilized, with $59.5 million used for the ongoing development of the DurAVR® Transcatheter Heart Valve and $20.5 million used for debt repayment, working capital, and other corporate purposes.